{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:19:18Z","timestamp":1780474758958,"version":"3.54.1"},"reference-count":32,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.3960\/jslrt.19039","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T22:04:49Z","timestamp":1589321089000},"page":"41-50","source":"Crossref","is-referenced-by-count":17,"title":["The clinical impact of absolute lymphocyte count in peripheral blood                    among patients with methotrexate - associated lymphoproliferative                    disorders"],"prefix":"10.3960","volume":"60","author":[{"given":"Michihide","family":"Tokuhira","sequence":"first","affiliation":[{"name":"Department of Hematology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Tomikawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoe","family":"Anan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihiko","family":"Sagawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihiro","family":"Higashi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuju","family":"Momose","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology,                            Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama,                            Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Tabayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Nakaseko","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Tamaru","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical                            Center, Saitama Medical University, Kawagoe, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Gaulard P, Swerdlow SH, Harris NL, Sundstrdm                    C, Jaffe ES. Other iatrogenic immunodeficiency-associated lymphoproliferative                    disorders. In: Swerdlow SH, Campo E, Harris NL, <i>et al<\/i>. (eds):                    WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed,                    Lyon, IARC. 2017, pp. 462-444."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Kamel                            OW, van                                de Rijn                            M,                                Weiss                            LM                    <i>et al.<\/i> Brief report: reversible lymphomas associated with                    Epstein-Barr virus occurring during methotrexate therapy for rheumatoid                    arthritis and dermatomyositis. N Engl J Med. 1993; 328: 1317-1321.","DOI":"10.1056\/NEJM199305063281806"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Kamel                            OW, Van                                De Run                            M,                                Hanasono                            MM,                                Warnke                            RA.                    Immunosuppression-associated lymphoproliferative disorders in rheumatic                    patients. Leuk Lymphoma. 1995; 16: 363-369.","DOI":"10.3109\/10428199509054421"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Hoshida                            Y,                                Tomita                            Y,                                Zhiming                            D                    <i>et al.<\/i> Lymphoproliferative disorders in autoimmune diseases in                    Japan: analysis of clinicopathological features and Epstein-Barr virus                    infection. Int J Cancer. 2004; 108: 443-449.","DOI":"10.1002\/ijc.11582"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Tokuhira                            M,                                Tamaru                            J,                                Kizaki                            M. Clinical                    management for other iatrogenic immunodeficiency-associated lymphoproliferative                    disorders. J Clin Exp Hematop. 2019; 59: 72-92.","DOI":"10.3960\/jslrt.19007"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Hasserjian                            RP,                                Chen                            S,                                Perkins                            SL                    <i>et al.<\/i> Immunomodulator agent-related lymphoproliferative                    disorders. Mod Pathol. 2009; 22: 1532-1540.","DOI":"10.1038\/modpathol.2009.131"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Tokuhira                            M,                                Watanabe                            R,                                Nemoto                            T                    <i>et al.<\/i> Clinicopathological analyses in patients with other                    iatrogenic immunodeficiency-associated lymphoproliferative diseases and                    rheumatoid arthritis. Leuk Lymphoma. 2012; 53: 616-623.","DOI":"10.3109\/10428194.2011.625101"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ichikawa                            A,                                Arakawa                            F,                                Kiyasu                            J                    <i>et al.<\/i> Methotrexate\/iatrogenic lymphoproliferative disorders in                    rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important                    predictors of disease progression and regression. Eur J Haematol. 2013; 91:                    20-28.","DOI":"10.1111\/ejh.12116"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Gion                            Y,                                Iwaki                            N,                                Takata                            K                    <i>et al.<\/i> Clinicopathological analysis of methotrexate-associated                    lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and                    classical Hodgkin lymphoma types. Cancer Sci. 2017; 108: 1271-1280.","DOI":"10.1111\/cas.13249"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Harigai                            M.                    Lymphoproliferative disorders in patients with rheumatoid arthritis in the era                    of widespread use of methotrexate: A review of the literature and current                    perspective. Mod Rheumatol. 2018; 28: 1-8.","DOI":"10.1080\/14397595.2017.1352477"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Tokuhira                            M,                                Saito                            S,                                Okuyama                            A                    <i>et al.<\/i> Clinicopathologic investigation of methotrexate-induced                    lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma. 2018;                    59: 1143-1152.","DOI":"10.1080\/10428194.2017.1369073"},{"key":"12","unstructured":"12 Kurita D, Miyoshi H, Ichikawa A, <i>et                        al<\/i>. Clinicopathological Study of Methotrexate-Associated                    Lymphoproliferative Disorders in Rheumatoid Arthritis Patients: Histological                    Classification and Predictive Factors for Disease Progression. 2017; Atlanta,                    ASH meeting #4168."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Takanashi                            S,                                Nakazato                            T,                                Aisa                            Y                    <i>et al.<\/i> The prognostic value of positron emission                    tomography\/computed tomography in rheumatoid arthritis patients with                    methotrexate-associated lymphoproliferative disorders. Ann Hematol. 2018; 97:                    1611-1618.","DOI":"10.1007\/s00277-018-3327-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kobayashi                            S,                                Kikuchi                            Y,                                Sato                            K                    <i>et al.<\/i> Reversible iatrogenic, MTX-associated EBV-driven                    lymphoproliferation with histopathological features of a lymphomatoid                    granulomatosis in a patient with rheumatoid arthritis. Ann Hematol. 2013; 92:                    1561-1564.","DOI":"10.1007\/s00277-013-1741-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Inui                            Y,                                Matsuoka                            H,                                Yakushijin                            K                    <i>et al.<\/i> Methotrexate-associated lymphoproliferative disorders:                    management by watchful waiting and observation of early lymphocyte recovery                    after methotrexate withdrawal. Leuk Lymphoma. 2015; 56: 3045-3051.","DOI":"10.3109\/10428194.2015.1022769"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Saito                            S,                                Kaneko                            Y,                                Yamaoka                            K,                                Tokuhira                            M,                                Takeuchi                            T. Distinct                    patterns of lymphocyte count transition in lymphoproliferative disorder in                    patients with rheumatoid arthritis treated with methotrexate. Rheumatology.                    2017; 56: 940-946.","DOI":"10.1093\/rheumatology\/kex002"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Saito                            S,                                Suzuki                            K,                                Yoshimoto                            K                    <i>et al.<\/i> Restoration of decreased T helper 1 and CD8+ T cell                    subsets is associated with regression of lymphoproliferative disorders developed                    during methotrexate treatment. Front Immunol. 2018; 9: 621.","DOI":"10.3389\/fimmu.2018.00621"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Takanashi                            S,                                Aisa                            Y,                                Ito                            C                    <i>et al.<\/i> Clinical characteristics of methotrexate-associated                    lymphoproliferative disorders: relationship between absolute lymphocyte count                    recovery and spontaneous regression. Rheumatol Int. 2017; 37: 1629-1633.","DOI":"10.1007\/s00296-017-3764-8"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Maegawa                            S,                                Kuroda                            J,                                Kobayashi                            T                    <i>et al.<\/i> Clinical manifestation and prognostic factors of 32                    Japanese patients with autoimmune disease-associated diffuse large B-cell                    lymphoma. Leuk Lymphoma. 2015; 56: 785-788.","DOI":"10.3109\/10428194.2014.928936"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Hashimoto                            A,                                Chiba                            N,                                Tsuno                            H                    <i>et al.<\/i> Incidence of malignancy and the risk of lymphoma in                    Japanese patients with rheumatoid arthritis compared to the general population.                    J Rheumatol. 2015; 42: 564-571.","DOI":"10.3899\/jrheum.140533"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Komatsuda                            A,                                Wakui                            H,                                Nimura                            T,                                Sawada                            K. Reversible                    infliximab-related lymphoproliferative disorder associated with Epstein-Barr                    virus in a patient with rheumatoid arthritis. Mod Rheumatol. 2008; 18: 315-318.","DOI":"10.3109\/s10165-008-0053-0"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Wolfe                            F,                                Michaud                            K. The effect of                    methotrexate and anti\u2013tumor necrosis factor therapy on the risk of lymphoma in                    rheumatoid arthritis in 19,562 patients during 89,710 PERSON-YEARS of                    observation. Arthritis Rheum. 2007; 56: 1433-1439.","DOI":"10.1002\/art.22579"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Nocturne                            G,                                Boudaoud                            S,                                Ly                            B                    <i>et al.<\/i> Impact of anti-TNF therapy on NK cells function and on                    immunosurveillance against B-cell lymphomas. J Autoimmun. 2017; 80: 56-64.","DOI":"10.1016\/j.jaut.2017.02.001"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Balandraud                            N,                                Meynard                            JB,                                Auger                            I                    <i>et al.<\/i> Epstein-Barr virus load in the peripheral blood of                    patients with rheumatoid arthritis: accurate quantification using real-time                    polymerase chain reaction. Arthritis Rheum. 2003; 48: 1223-1228.","DOI":"10.1002\/art.10933"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Sawada                            S,                                Takei                            M. Epstein-Barr                    virus etiology in rheumatoid synovitis. Autoimmun Rev. 2005; 4: 106-110.","DOI":"10.1016\/j.autrev.2004.08.034"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Kanda                            Y. Investigation                    of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone                    Marrow Transplant. 2013; 48: 452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Ishida                            Y,                                Agata                            Y,                                Shibahara                            K,                                Honjo                            T. Induced                    expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon                    programmed cell death. EMBO J. 1992; 11: 3887-3895.","DOI":"10.1002\/j.1460-2075.1992.tb05481.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Stav                            I,                                Gyawali                            B,                                Goldstein                            DA. Duration of                    adjuvant immunotherapy\u2014biologic, clinical and economic considerations. Med                    Oncol. 2018; 35: 160.","DOI":"10.1007\/s12032-018-1218-0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Hasenclever                            D,                                Diehl                            V,                                Armitage                            JO                    <i>et al.<\/i> International prognostic factors project on advanced                    Hodgkin\u2019s disease. A prognostic score for advanced Hodgkin\u2019s disease. N Engl J                    Med. 1998; 339: 1506-1514.","DOI":"10.1056\/NEJM199811193392104"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Vassilakopoulos                            TP,                                Dimopoulou                            MN,                                Angelopoulou                            MK                    <i>et al.<\/i> Prognostic implication of the absolute lymphocyte to                    absolute monocyte count ratio in patients with classical Hodgkin lymphoma                    treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent                    regimens. Oncologist. 2016; 21: 343-353.","DOI":"10.1634\/theoncologist.2015-0251"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Keane                            C,                                Tobin                            J,                                Talaulikar                            D                    <i>et al.<\/i> A high LDH to absolute lymphocyte count ratio in                    patients with DLBCL predicts for a poor intratumoral immune response and                    inferior survival. Oncotarget. 2018; 9: 23620-23627.","DOI":"10.18632\/oncotarget.25306"},{"key":"32","unstructured":"32 Li                            N,                                Zhang                            L,                                Song                            H                    <i>et al.<\/i> Prognostic impact of absolute lymphocyte count\/absolute                    monocyte count ratio and prognostic score in patients with nasal-type,                    extranodal natural killer\/T-cell lymphoma. Tumour Biol. 2017; 39: 1010428317705503."}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/2\/60_19039\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T04:28:22Z","timestamp":1592627302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/2\/60_19039\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.19039","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}